Premium
Molecular and cytogenetic studies of a patient with philadelphia‐negative, BCR ‐positive chronic myeloid leukemia and t(12;12)(q13;p12)
Author(s) -
Zaccaria Alfonso,
Testoni Nicoletta,
Tassinari Angela,
Celso Bommina,
Emanuel Beverly S.,
Budarf Marcia,
Saglio Giuseppe,
Guerrasio Angelo,
Barletta Cosimo,
Peschle Cesare,
Tura Sante
Publication year - 1990
Publication title -
genes, chromosomes and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.754
H-Index - 119
eISSN - 1098-2264
pISSN - 1045-2257
DOI - 10.1002/gcc.2870010405
Subject(s) - breakpoint cluster region , myeloid leukemia , chromosomal translocation , philadelphia chromosome , breakpoint , cancer research , abl , leukemia , microbiology and biotechnology , biology , medicine , chemistry , genetics , gene , receptor , tyrosine kinase
A patient with Philadelphia (Ph 1 )‐negative, breakpoint cluster region (bcr)‐positive chronic myeloid leukemia (CML) is reported. Pulsed‐field gel electrophoretic analysis demostrated the comigration of both ABL and BCR sequences on the same Bss 1–111 and Sac 11 fragment. Moreover, in situ hybridization studies demonstrated that ABL sequences had been moved from band 9q34 to 22q11 and that the additional t(12;12)(q13;p12) was not involved in the ABL/BCR related translocation. Neverthless, a possible role of oncogenes or regulatory sequences activated or inhibited by the additional translocation cannot be excluded.